OTCMKTS:VYYRF Voyageur Pharmaceuticals (VYYRF) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free VYYRF Stock Alerts $0.05 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.04▼$0.0852-Week Range$0.00▼$0.08VolumeN/AAverage Volume10,891 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Voyageur Pharmaceuticals alerts: Email Address Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Voyageur Pharmaceuticals Stock (OTCMKTS:VYYRF)Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products in the province of British Columbia, Canada, and the state of Utah. It develops barium, iodine-based APIs, and imaging contrast agents for medical radiology. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.Read More VYYRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYYRF Stock News HeadlinesMay 28, 2024 | proactiveinvestors.comVoyageur Pharmaceuticals wins US$1.9M sales contract for SmoothX 2% barium contrast productMay 27, 2024 | finance.yahoo.comVoyageur Pharmaceuticals Ltd Signs Radiology Drug Sales Contract Valued at $USD 1.9 Million for SmoothX 2% Barium ContrastMarch 5, 2024 | proactiveinvestors.comVoyageur Pharmaceuticals poised to shake up medical imaging market with API partnershipMarch 4, 2024 | proactiveinvestors.comVoyageur Pharmaceuticals to fast-track commercialization of imaging contrast agents through API partnershipSeptember 28, 2023 | finance.yahoo.comVoyageur Pharmaceuticals "sees a gap in the market" for domestically-produced bariumAugust 3, 2023 | msn.comVoyageur Pharmaceuticals GAAP EPS of -$0.51, revenue of $4.85MJune 6, 2023 | proactiveinvestors.comVoyageur Pharmaceuticals with a "big market to go for"May 26, 2023 | proactiveinvestors.comVoyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugsMay 24, 2023 | finance.yahoo.comThe Power Play by The Market Herald Releases New Interviews with Solar Alliance, Cleantek Industries, Voyageur Pharmaceuticals and Homerun Resources Discussing Their Latest NewsApril 13, 2023 | finance.yahoo.comVoyageur Pharmaceuticals' SmoothX abdominal diagnostic drink gets high praise in comparative studyApril 11, 2023 | finance.yahoo.comThe Power Play by The Market Herald Releases New Interviews with Luminex Resources, Voyageur Pharmaceuticals, Trillion Energy, ARway and Pan Global Resources Discussing Their Latest NewsJanuary 23, 2023 | proactiveinvestors.comVoyageur Pharmaceuticals is pursing an innovative 'earth to bottle' model through its ownership of natural barium and iodine resourcesJanuary 13, 2023 | proactiveinvestors.comVoyageur Pharmaceuticals increases maximum size of its non-brokered private placement to $1.2M due to strong investor demandNovember 30, 2022 | finance.yahoo.comThe Power Play by The Market Herald Releases New Interviews with Trillion, Gamelancer, INEO Tech, ACME Lithium and Voyageur Discussing Their Latest NewsNovember 29, 2022 | finance.yahoo.comInvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Completed Production of a Test Batch of its SmoothX™ Barium Sulfate CT Contrast Media Oral Suspension for the Canadian CT Imaging MarketNovember 28, 2022 | proactiveinvestors.comVoyageur Pharmaceuticals completes production testing of SmoothX; begins scale-up for Canadian imaging marketNovember 28, 2022 | finance.yahoo.comVoyageur Pharmaceuticals Ltd. Completes Medical Imaging CT Contrast Agent Production Testing and Begins Production Scale-up of SmoothX(TM)November 1, 2022 | finance.yahoo.comInvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Completion of the design of its Carbon Neutral Pharmaceutical Facility and Accelerated Revenue Generation Timeline for its Frances Creek Barium Sulfate ProjectOctober 31, 2022 | proactiveinvestors.comVoyageur Pharmaceuticals accelerates revenue generation timeline for Frances Creek barium sulphate projectOctober 26, 2022 | finance.yahoo.comInvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ MOU with Rain Cage Carbon to Develop Fullerene-Based Medical Contrast Agents from Carbon Capture of Hydrocarbon Exhaust SystemsOctober 25, 2022 | proactiveinvestors.comVoyageur Pharmaceuticals says Rain Cage Carbon deal will make it a carbon neutral manufacturerOctober 24, 2022 | proactiveinvestors.comVoyageur Pharmaceuticals signs MOU to develop fullerene contrast agents for medical imaging applications and carbon capture technologyOctober 12, 2022 | proactiveinvestors.comVoyageur Pharmaceuticals in the right space at the right time with its 'earth-to-bottle' modelSeptember 23, 2022 | finance.yahoo.comInvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Notice of Work with the BC Ministry of Mines, for the Removal of 2,000 Tonnes of Barium Sulfate from its Frances Creek ProjectJune 16, 2022 | finance.yahoo.comVoyageur Mineral Explorers Corp. Options North Star - Gold Rock ProjectSee More Headlines Receive VYYRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyageur Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:VYYRF CUSIPN/A CIKN/A Webwww.voyageurminerals.ca Phone(587) 779-6166FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Brent Willis Bsc.Eng (Age 53)President, CEO & Director Comp: $96.03kMr. Bradley Craig Willis P.Eng. (Age 53)Founder, COO & Director Comp: $92kMr. Albert DeslauriersChief Financial OfficerMr. Ethan MohanSales ManagerKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors VYYRF Stock Analysis - Frequently Asked Questions How have VYYRF shares performed in 2024? Voyageur Pharmaceuticals' stock was trading at $0.04 at the start of the year. Since then, VYYRF shares have increased by 12.5% and is now trading at $0.0450. View the best growth stocks for 2024 here. How do I buy shares of Voyageur Pharmaceuticals? Shares of VYYRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VYYRF) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyageur Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
